PMID- 20845616
OWN - NLM
STAT- MEDLINE
DCOM- 20101109
LR  - 20181201
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 56
IP  - 8
DP  - 2010 Aug
TI  - [Comprehensive management of cardiovascular risk. Focusing on telmisartan].
PG  - 839-44
AB  - Cardiovascular diseases (CVD) represent a significant health problem in all 
      countries world-wide and in the developed world, including the Czech Republic, in 
      particular. The underlying cause in the majority of CVD patients is 
      atherosclerosis and its complications, respectively. The present paper focuses on 
      prevention and timely treatment of atherosclerosis. Management should be 
      comprehensive and should target the risk factors (RF). Hypertension, 
      hyperlipoproteinaemia and dyslipidemia (HLP and DLP), type 2 diabetes mellitus 
      (T2DM), visceral fat obesity and cigarette smoking are the dominating RFs. Even 
      though all RFs have to be managed simultaneously and it is not possible to focus 
      on just one of them, for the sake of clarity, this paper discusses hypertension 
      and the use of telmisartan, a representative of one the most up-to-date group of 
      antihypertensives. There is a growing evidence that it is not always just a 
      reduction of a specific risk that is important but also the mode of treatment. 
      For example, to reduce a CV risk in a patient with hypertension but also, for 
      example, with metabolic syndrome, it is more beneficial to treat the patient with 
      rennin-angiotensin system (RAS) blocking agents, possibly in a combination with 
      calcium channels antagonists, than to use "traditional" (older) treatment 
      approach with a combination of a beta/blocker and diuretic. Among the 
      RAS-modifying agents, ACE inhibitors and sartans are the most widely used. Among 
      sartans, telmisartan is very well-tolerated and has evidence from a large 
      interventional study for its effect on reducing the CV risk.
FAU - Ceska, R
AU  - Ceska R
AD  - Centrum preventivn kardiologie III. interni kliniky 1. lekarske fakulty UKa VFN 
      Praha. rcesk@lf1.cuni.cz
FAU - Krutska, S
AU  - Krutska S
FAU - Zlatohlavek, L
AU  - Zlatohlavek L
FAU - Vrablik, M
AU  - Vrablik M
LA  - cze
PT  - Journal Article
PT  - Review
TT  - Komplexni lecba kardiovaskularniho rizika. Zamereno na telmisartan.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - U5SYW473RQ (Telmisartan)
SB  - IM
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Antihypertensive Agents/*therapeutic use
MH  - Atherosclerosis/*drug therapy
MH  - Benzimidazoles/*therapeutic use
MH  - Benzoates/*therapeutic use
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Humans
MH  - Risk Factors
MH  - Telmisartan
EDAT- 2010/09/18 06:00
MHDA- 2010/11/10 06:00
CRDT- 2010/09/18 06:00
PHST- 2010/09/18 06:00 [entrez]
PHST- 2010/09/18 06:00 [pubmed]
PHST- 2010/11/10 06:00 [medline]
PST - ppublish
SO  - Vnitr Lek. 2010 Aug;56(8):839-44.